


SRM

FGCZ

23 October 2017

Distribution of qValues



Histogram of qValues for all SRM assays. The red line indicates the qValue threshold - we control the False Discovery Rate (fdr) at this level.

Remove all transitions with more than X missing values

Histogram showing the number of missing values for the heavy peptides in all samples. The red line indicates the maximum of NA's allowed.

Histogram showing the number of missing values for the light peptides in all samples. The red line indicates the maximum of NA's allowed.




Figure 1: Distribution of NA's for heavy peptides




Figure 2: Distribution of NA's for light peptides.




Figure 3: Missing values $\log_2(L/H)$ per Transtion.




Figure 4: heatmap of log₂ fold changes transtion level
5

Heatmap of log₂(L/H)

Transitions dropped because of to many NA's in log₂ fold change.

Table 1: removed transitions (to many NA's)

Peptide.Sequence	Protein.Name	Precursor.Charge	Product.Charge	Fragment.Ion
AFYAELYHISSNLEK	sp Q9UL46 PSME2 HUMAN	2	1	b5
AFYAELYHISSNLEK	sp Q9UL46 PSME2 HUMAN	2	1	y6
AFYAELYHISSNLEK	sp Q9UL46 PSME2 HUMAN	2	1	y7
ALVILAK	sp Q99497 PARK7 HUMAN	2	1	y6
ASTPGAAAQIQEVK	sp P02730 B3AT HUMAN	2	1	y8
ASTPGAAAQIQEVK	sp P02730 B3AT HUMAN	2	1	y9
ASTPGAAAQIQEVK	sp P02730 B3AT HUMAN	2	2	y11
CAMLNPPNR	sp P19957 ELAF HUMAN	2	1	b3
CAMLNPPNR	sp P19957 ELAF HUMAN	2	1	y4
CAMLNPPNR	sp P19957 ELAF HUMAN	2	1	y7
CCPDTCGIK	sp P03973 SLPI HUMAN	2	1	b2
CCPDTCGIK	sp P03973 SLPI HUMAN	2	1	y5
CCPDTCGIK	sp P03973 SLPI HUMAN	2	1	y7
DSPSVWAAVPGK	sp P07737 PROF1 HUMAN	2	2	b10
DTDIVDEAIYYFK	sp O15145 ARPC3 HUMAN	2	2	y4
FNLTETSEAEIHQSFQHLLR	sp P01011-1 AACT HUMAN	3	1	y9
FNLTETSEAEIHQSFQHLLR	sp P01011-1 AACT HUMAN	3	2	y14
FNLTETSEAEIHQSFQHLLR	sp P01011-1 AACT HUMAN	3	2	y15
FNLTETSEAEIHQSFQHLLR	sp P01011-1 AACT HUMAN	3	2	y16
FPNPHQPPK	sp Q8TAX7 MUC7 HUMAN	2	1	y3
FPNPHQPPK	sp Q8TAX7 MUC7 HUMAN	2	1	y6
GDTANEIGQVLHFENVK	sp P36952-1 SPB5 HUMAN	2	1	y5
GDTANEIGQVLHFENVK	sp P36952-1 SPB5 HUMAN	2	1	y6
GDTANEIGQVLHFENVK	sp P36952-1 SPB5 HUMAN	2	1	y7
GMHGGVPGGK	sp Q9GZZ8 LACRT HUMAN	2	1	y4
GMHGGVPGGK	sp Q9GZZ8 LACRT HUMAN	2	1	y7
GMHGGVPGGK	sp Q9GZZ8 LACRT HUMAN	2	2	y8
GNPTVEVDLFTSK	sp P06733-1 ENOA HUMAN	2	1	y6
GNPTVEVDLFTSK	sp P06733-1 ENOA HUMAN	2	1	y8
GPVSTKPGSCPIILIR	sp P19957 ELAF HUMAN	3	1	y6
GQETSTNPIASIFAWTR	sp O75874 IDHC HUMAN	2	1	y5
GQETSTNPIASIFAWTR	sp O75874 IDHC HUMAN	2	1	y7
GQETSTNPIASIFAWTR	sp O75874 IDHC HUMAN	2	1	y8
GWVIHPLGLR	sp P02730 B3AT HUMAN	2	1	y5
GWVIHPLGLR	sp P02730 B3AT HUMAN	2	1	y6
GWVIHPLGLR	sp P02730 B3AT HUMAN	2	1	y7
IGLLVK	sp P46940 IQGA1 HUMAN	2	1	y4
INVNEIFYDLVR	sp P62834 RAP1A HUMAN	2	1	y5
INVNEIFYDLVR	sp P62834 RAP1A HUMAN	2	1	y6
INVNEIFYDLVR	sp P62834 RAP1A HUMAN	2	1	y7
ITTLPNVTFLPQNATTISSR	sp Q8TAX7 MUC7 HUMAN	3	1	y6
ITTLPNVTFLPQNATTISSR	sp Q8TAX7 MUC7 HUMAN	3	1	y8
ITTLPNVTFLPQNATTISSR	sp Q8TAX7 MUC7 HUMAN	3	2	y10
KPECQSDWQCPGK	sp P03973 SLPI HUMAN	3	1	y3
KPECQSDWQCPGK	sp P03973 SLPI HUMAN	3	1	y4
KPECQSDWQCPGK	sp P03973 SLPI HUMAN	3	1	y5

Peptide.Sequence	Protein.Name	Precursor.Charge	Product.Charge	Fragment.Ion
LGLAPQIQDLYGK	sp P46940 IQGA1 HUMAN	2	1	y6
LGLAPQIQDLYGK	sp P46940 IQGA1 HUMAN	2	2	b9
LQFHADVAGDIFHQQCK	sp P11413-1 G6PD HUMAN	3	1	y5
LQFHADVAGDIFHQQCK	sp P11413-1 G6PD HUMAN	3	1	y6
LQFHADVAGDIFHQQCK	sp P11413-1 G6PD HUMAN	3	2	y9
LSVPDGFK	sp P02730 B3AT HUMAN	2	1	y7
LSYLDVYLIHWPQGFK	sp O60218 AK1BA HUMAN	3	1	y5
LSYLDVYLIHWPQGFK	sp O60218 AK1BA HUMAN	3	2	y12
LSYLDVYLIHWPQGFK	sp O60218 AK1BA HUMAN	3	2	y14
LVSGWVKPIIIGR	sp O75874 IDHC HUMAN	3	1	y6
LVSGWVKPIIIGR	sp O75874 IDHC HUMAN	3	2	y6
LYGSEAFATDFQDSAAAK	sp P01011-1 AACT HUMAN	2	1	y5
LYGSEAFATDFQDSAAAK	sp P01011-1 AACT HUMAN	2	1	y8
LYGSEAFATDFQDSAAAK	sp P01011-1 AACT HUMAN	2	1	y9
QDGSVDFGR	sp P02675 FIBB HUMAN	2	1	b5
SHFELPHYPGLLAHQKPFIR	sp Q8TAX7 MUC7 HUMAN	3	1	y4
SHFELPHYPGLLAHQKPFIR	sp Q8TAX7 MUC7 HUMAN	3	1	y6
SHFELPHYPGLLAHQKPFIR	sp Q8TAX7 MUC7 HUMAN	3	2	y12
STASFEELCSEYR	sp Q9NQ38-3 ISK5 HUMAN	2	1	y5
STASFEELCSEYR	sp Q9NQ38-3 ISK5 HUMAN	2	1	y6
STASFEELCSEYR	sp Q9NQ38-3 ISK5 HUMAN	2	1	y7
SWLAELQQWLKPLK	sp P08571 CD14 HUMAN	3	1	y4
SWLAELQQWLKPLK	sp P08571 CD14 HUMAN	3	1	y5
SWLAELQQWLKPLK	sp P08571 CD14 HUMAN	3	1	y6
TVEAEEAAHGTVTR	sp O75874 IDHC HUMAN	2	1	y6
TVEAEEAAHGTVTR	sp O75874 IDHC HUMAN	2	2	y11
VCSTWGFDFHYK	sp Q9HC84 MUC5B HUMAN	3	1	y7
VEAFQTTISK	sp Q9UL46 PSME2 HUMAN	2	1	y6
VEAFQTTISK	sp Q9UL46 PSME2 HUMAN	2	1	y7
VEAFQTTISK	sp Q9UL46 PSME2 HUMAN	2	1	y8
VPFNGQDPVK	sp P19957 ELAF HUMAN	2	1	y3
VPFNGQDPVK	sp P19957 ELAF HUMAN	2	1	y8
VPFNGQDPVK	sp P19957 ELAF HUMAN	2	2	y9
VSLDVNHFAPDELTVK	sp P04792 HSPB1 HUMAN	2	1	b9
VSLDVNHFAPDELTVK	sp P04792 HSPB1 HUMAN	2	1	y7
VSLDVNHFAPDELTVK	sp P04792 HSPB1 HUMAN	2	1	y8
VWVLQDQTLIAVPR	sp Q9UHA7 IL1F6 HUMAN	2	1	b3
VWVLQDQTLIAVPR	sp Q9UHA7 IL1F6 HUMAN	2	1	y4
VWVLQDQTLIAVPR	sp Q9UHA7 IL1F6 HUMAN	2	1	y5
WWTCFVK	sp O15145 ARPC3 HUMAN	2	1	y3
WWTCFVK	sp O15145 ARPC3 HUMAN	2	1	y5
WWTCFVK	sp O15145 ARPC3 HUMAN	2	1	y6

Peptide Quantification

The following plots show $\text{Log}_2(\text{H/L})$ of peptides belonging to the same proteins (y axis) given samples (x axis). These fold changes will be used to compute the fold H/L fold change of the protein in a sample.

Remove all peptides with only one transition.

Table 2: peptides removed since only a single valid transition

Peptide.Sequence	Protein.Name	Precursor.Charge	Product.Charge	Fragment.Ion
ELGQVVECSLDFGLVCR	sp Q9HC84 MUC5B HUMAN	2	1	y10
FPNPHQPPK	sp Q8TAX7 MUC7 HUMAN	2	2	y8
GNPTVEVDLFTSK	sp P06733-1 ENOA HUMAN	2	1	y3
LGLAPQIQDLYGK	sp P46940 IQGA1 HUMAN	2	1	y3
LVSGWVKPIIIGR	sp O75874 IDHC HUMAN	3	2	y11
TVEAEAAHGTVTR	sp O75874 IDHC HUMAN	2	1	y7

Removing decorrelated

List of peptides removed

Peptides might have been removed since there were no quantified transtions, only a single transition was quantified or the transition were uncorrelated.

Table 3: All removed peptides.

Protein.Name	Peptide.Sequence	Precursor.Charge
sp Q9UL46 PSME2 HUMAN	AFYAELYHISSNLEK	2
sp P02730 B3AT HUMAN	ASTPGAAAQIQEVK	2
sp P19957 ELAF HUMAN	CAMLNPPNR	2
sp P03973 SLPI HUMAN	CCPDTCGIK	2
sp Q9HC84 MUC5B HUMAN	ELGQVVECSLDFGLVCR	2
sp P01011-1 AACT HUMAN	FNLTETSEAEIHQSFQHLLR	3
sp P08571 CD14 HUMAN	FPAIQNLALR	2
sp Q8TAX7 MUC7 HUMAN	FPNPHQPPK	2
sp P36952-1 SPB5 HUMAN	GDTANEIGQVLHFENVK	2
sp Q9GZZ8 LACRT HUMAN	GMHGGVPGGK	2
sp P06733-1 ENOA HUMAN	GNPTVEVDLFTSK	2
sp O75874 IDHC HUMAN	GQETSTNPIASIFAWTR	2
sp P02730 B3AT HUMAN	GWVIHPLGLR	2
sp P46940 IQGA1 HUMAN	IQLLVK	2
sp P62834 RAP1A HUMAN	INVNEIFYDLVR	2
sp Q8TAX7 MUC7 HUMAN	ITTLPNVTFLPQNATTISSR	3
sp P03973 SLPI HUMAN	KPECQSDWQCPGK	3
sp P46940 IQGA1 HUMAN	LGLAPQIQDLYGK	2
sp P11413-1 G6PD HUMAN	LQFHDVAGDIFHQQCK	3
sp O60218 AK1BA HUMAN	LSYLDVYLIHWPQGFK	3
sp O75874 IDHC HUMAN	LVSGWVKPIIIGR	3
sp P01011-1 AACT HUMAN	LYGSEAFATDFQDSAAAK	2
sp Q8TAX7 MUC7 HUMAN	SHFELPHYPGLLAHQKPFIR	3
sp Q9NQ38-3 ISK5 HUMAN	STASFEELCSEYR	2
sp P08571 CD14 HUMAN	SWLAELQQWLKPGLK	3
sp O75874 IDHC HUMAN	TVEAEAAHGTVTR	2
sp Q9UL46 PSME2 HUMAN	VEAFQTTISK	2
sp P19957 ELAF HUMAN	VPFNGQDPVK	2
sp P04792 HSPB1 HUMAN	VSLDVNHFAPDELTVK	2
sp Q9UHA7 IL1F6 HUMAN	VWVLQDQTLIAVPR	2
sp O15145 ARPC3 HUMAN	WWTCFVK	2


List of peptides used for quantification

Table 4: Peptides Still available and Nr of transitions per peptide.
Columns charge state.


	2	3
AAQVTIQSSGTFSSK	3	0
ADLSGITGAR	3	0
AFDQDGDGHITVDELR	3	0
AGLEDLQVAFR	3	0
ALHFAISEYNK	3	0
ALVILAK	2	0
ATAPTELNCDDFK	3	0
ATSIVAWLAK	3	0
AVFLTEALER	3	0
AYLQQLR	3	0
CADSSFTVLAELR	3	0
CLDPVDTPNPTR	4	0
CVAELGPQAVGAVK	3	0
DGLILTSR	3	0
DNENVVNEYSSELEK	5	0
DSPSVWAAVPGK	2	0
DTDIVDEAIYYFK	2	0
EDGGGWYNR	3	0
ELSTVQESFLVK	3	0
GPVSTKPGSCPIILIR	0	2
HHCPSPTIILVGTK	0	3
IAVAAASKPAVEIK	0	3
IGAEVYHNLK	3	0
IGFPWSEIR	3	0
IIELPFQNK	3	0
IIPGGIYNADLNDEWVQR	3	0
ILVNAAAYFVGK	3	0
IVENIQVFDFK	3	0
IWDVNQK	3	0
LAPITYPQGLALAK	3	0
LATQSNEITIPVTFESR	3	0
LEDFAR	3	0
LFDQAFGLPR	3	0
LFFLQVK	3	0
LGNFFSPK	2	0
LLLSSLGIPVNHLEGSQK	0	3
LQLEAVNITDLSNR	3	0
LSVPDGFK	2	0
LTVGAAQVPAQLLVGALR	0	3
LVLVNAIYFK	3	0
LVVLGSGGVGK	3	0
NNQLVAGYLQGPVNLLEEK	3	0
NQGNTWLTAFLVK	3	0
QDGSVDFGR	3	0
QFIENGSEFAQK	3	0
QGHNSVFLIK	0	3
SASLHLPK	3	0

	2	3
SENFEECLK	3	0
SFLFYHSQSGR	3	0
SGAQATWTELPWPHEK	0	3
SGNEDEFR	3	0
SGYLSSER	3	0
SILLTEQALAK	3	0
SSFYVNGLTTLGGQK	3	0
SVLGQLGITK	3	0
SYPGLTSYLVR	3	0
TAAQVLIR	3	0
TFHFNTVEEVHSR	0	3
TFVNITPAEVGVLVGK	3	0
TFVPGCQPGFETLGNIK	3	0
TSIVHLFEWR	3	0
TYGADLASVDFQHASEDAR	0	3
VCLDLSPGYSDVK	3	0
VCSTWGDHFYK	0	2
VFSNGADLSGVTEEAPLK	3	0
VGDQPTLQLK	3	0
VGEEFEEQTVDGRPCK	0	3
VSVQLEASPAFLAVPVEK	4	0
VTVAGLAGK	3	0
VWVYPPEK	3	0
WDGVPFILR	3	0
WVDIALECER	3	0
WYVVGLAGNAILR	3	0
YDPTIEDSYR	3	0
YISPDQLADLYK	4	0
YLECSALTQR	3	0

Peptide Intensities



Protein Intensities



List of quantified proteins

Table 5: Quantified proteins with number of peptides used for quantification

Protein	NrPeptides
sp A8K2U0 A2ML1 HUMAN	3
sp O15145 ARPC3 HUMAN	2
sp O60218 AK1BA HUMAN	2
sp P01009-1 A1AT HUMAN	3
sp P01011-1 AACT HUMAN	1
sp P01023 A2MG HUMAN	3
sp P01037 CYTN HUMAN	2
sp P02675 FIBB HUMAN	3
sp P02730 B3AT HUMAN	1
sp P02790 HEMO HUMAN	3
sp P03973 SLPI HUMAN	1
sp P04792 HSPB1 HUMAN	2
sp P06733-1 ENOA HUMAN	2
sp P07737 PROF1 HUMAN	3
sp P08571 CD14 HUMAN	1
sp P11413-1 G6PD HUMAN	2
sp P15153 RAC2 HUMAN	3
sp P15311 EZRI HUMAN	3
sp P18510-1 IL1RA HUMAN	3
sp P19957 ELAF HUMAN	1
sp P19961 AMY2B HUMAN	3
sp P29373 RABP2 HUMAN	3
sp P30740 ILEU HUMAN	3
sp P36952-1 SPB5 HUMAN	2
sp P46940 IQGA1 HUMAN	1
sp P62834 RAP1A HUMAN	2
sp P80188-1 NGAL HUMAN	3
sp Q96QR1 SG3A1 HUMAN	2
sp Q99497 PARK7 HUMAN	3
sp Q9GZZ8 LACRT HUMAN	2
sp Q9HC84 MUC5B HUMAN	2
sp Q9NQ38-3 ISK5 HUMAN	2
sp Q9NZT1 CALL5 HUMAN	2
sp Q9UHA7 IL1F6 HUMAN	2

List of proteins not quantified

proteins


sp|Q9UL46|PSME2|HUMAN

sp|Q8TAX7|MUC7|HUMAN


sp|O75874|IDHC|HUMAN

Peptide profiles per Protein



sp|A8K2U0|A2ML1|HUMAN





sp|O15145|ARPC3|HUMAN




sp|O60218|AK1BA|HUMAN





sp|P01009-1|A1AT|HUMAN





sp|P01011-1|AACT|HUMAN





sp|P01023|A2MG|HUMAN




sp|P01037|CYTN|HUMAN





sp|P02675|FIBB|HUMAN




sp|P02730|B3AT|HUMAN





sp|P02790|HEMO|HUMAN





sp|P03973|SLPI|HUMAN





sp|P04792|HSPB1|HUMAN




sp|P06733-1|ENOA|HUMAN





sp|P07737|PROF1|HUMAN




sp|P08571|CD14|HUMAN




sp|P11413-1|G6PD|HUMAN




sp|P15153|RAC2|HUMAN




sp|P15311|EZRI|HUMAN




sp|P18510-1|IL1RA|HUMAN




sp|P19957|ELAF|HUMAN





sp|P19961|AMY2B|HUMAN





sp|P29373|RABP2|HUMAN




sp|P30740|ILEU|HUMAN





sp|P36952-1|SPB5|HUMAN




sp|P46940|IQGA1|HUMAN




sp|P62834|RAP1A|HUMAN





sp|P80188-1|NGAL|HUMAN





sp|Q96QR1|SG3A1|HUMAN




sp|Q99497|PARK7|HUMAN




sp|Q9GZZ8|LACRT|HUMAN





sp|Q9HC84|MUC5B|HUMAN





sp|Q9NQ38-3|ISK5|HUMAN



sp|Q9NZT1|CALL5|HUMAN




sp|Q9UHA7|IL1F6|HUMAN




Peptides used for quantification and their transitions


sp|A8K2U0|A2ML1|HUMAN_ATSIVAWLAK_2




sp|A8K2U0|A2ML1|HUMAN_ELSTVQESFLVK_2




sp|A8K2U0|A2ML1|HUMAN_VCLDLSPGYSDVK_2




sp|O15145|ARPC3|HUMAN_AYLQQLR_2




sp|O15145|ARPC3|HUMAN_DTDIVDEAIYYFK_2




sp|O60218|AK1BA|HUMAN_IVENIQVDFDK_2




sp|O60218|AK1BA|HUMAN_TAAQVLIR_2




sp|P01009-1|A1AT|HUMAN_SASLHLPK_2




sp|P01009-1|A1AT|HUMAN_SVLGQLGITK_2




sp|P01009-1|A1AT|HUMAN_VFSNGADLSGVTEEAPLK_2




sp|P01011-1|AACT|HUMAN_ADLSGITGAR_2




sp|P01023|A2MG|HUMAN_AAQVTIQSSGTFSSK_2




sp|P01023|A2MG|HUMAN_NQGNTWLTAFLVK_2




sp|P01023|A2MG|HUMAN_VSVQLEASPAFLAVPVEK_2




sp|P01037|CYTN|HUMAN_ALHFAISEYNK_2




sp|P01037|CYTN|HUMAN_IIPGGIYNADLNDEWVQR_2




sp|P02675|FIBB|HUMAN_DNENVVNEYSSELEK_2




sp|P02675|FIBB|HUMAN_EDGGGWYR_2




sp|P02675|FIBB|HUMAN_QDGSVDFGR_2




sp|P02730|B3AT|HUMAN_LSPVDGFK_2




sp|P02790|HEMO|HUMAN_QGHNSVFLIK_3




sp|P02790|HEMO|HUMAN_SGAQATWTLPWPHEK_3




sp|P02790|HEMO|HUMAN_VWVYPPEK_2




sp|P03973|SLPI|HUMAN_CLDPVDTNPTR_2





sp|P04792|HSPB1|HUMAN_LATQSNEITIPVTFESR_2





sp|P04792|HSPB1|HUMAN_LFDQAFGLPR_2




sp|P06733-1|ENOA|HUMAN_IGAEVYHNLK_2




sp|P06733-1|ENOA|HUMAN_YISPDQLADLYK_2




sp|P07737|PROF1|HUMAN_DSPSVWAAVPGK_2




sp|P07737|PROF1|HUMAN_SSFYVNGTLGGQK_2




sp|P07737|PROF1|HUMAN_TFVNITPAEVLVVGK_2




sp|P08571|CD14|HUMAN_LTVGAAQVPAQLLVGALR_3




sp|P11413-1|G6PD|HUMAN_LEDFFAR_2




sp|P11413-1|G6PD|HUMAN_WDGVPFILR_2




sp|P15153|RAC2|HUMAN_HHCPSTPIILVGTK_3




sp|P15153|RAC2|HUMAN_LAPITYPQGLALAK_2




sp|P15153|RAC2|HUMAN_YLECSALTQR_2




sp|P15311|EZRI|HUMAN_IGFPWSEIR_2





sp|P15311|EZRI|HUMAN_LFFLQVK_2





sp|P15311|EZRI|HUMAN_SGYLSSER_2




sp|P18510-1|IL1RA|HUMAN_IWDVNQK_2




sp|P18510-1|IL1RA|HUMAN_LQLEAVNITDLSENR_2




sp|P18510-1|IL1RA|HUMAN_NNQLVAGYLQGPVNVNLEEK_2




sp|P19957|ELAF|HUMAN_GPVSTKPGSCPIILIR_3




sp|P19961|AMY2B|HUMAN_SGNEDEFR_2




sp|P19961|AMY2B|HUMAN_TSIVHLFEWR_2




sp|P19961|AMY2B|HUMAN_WVDIALECR_2




sp|P29373|RABP2|HUMAN_IAVAAASKPAVEIK_3




sp|P29373|RABP2|HUMAN_SENFEELLK_2




sp|P29373|RABP2|HUMAN_VGEEFEEQTVDGRPCK_3




sp|P30740|ILEU|HUMAN_LVLVNAIFYK_2




sp|P30740|ILEU|HUMAN_TFHFNTVEEVHSR_3




sp|P30740||ILEU|HUMAN_TYGADLASVDFQHASEDAR_3




sp|P36952-1||SPB5|HUMAN_IIELPFQNK_2





sp|P36952-1|SPB5|HUMAN_ILVVNAAYFVGK_2





sp|P46940|IQGA1|HUMAN_LGNFFSPK_2




sp|P62834|RAP1A|HUMAN_LVVLGGVGVK_2




sp|P62834|RAP1A|HUMAN_YDPTIEDSYR_2




sp|P80188-1|NGAL|HUMAN_SYPGLTSYLVR_2




sp|P80188-1|NGAL|HUMAN_TFVPGCQPGEFTLGNIK_2




sp|P80188-1|NGAL|HUMAN_WYVVGLAGNAILR_2




sp|Q96QR1|SG3A1|HUMAN_CVAELGPQAVGAVK_2




sp|Q96QR1|SG3A1|HUMAN_LLLSSLGIPVNHIEGSQK_3




sp|Q99497|PARK7|HUMAN_ALVILAK_2




sp|Q99497|PARK7|HUMAN_DGLILTSR_2




sp|Q99497|PARK7|HUMAN_VTVAGLAGK_2




sp|Q9GZZ8|LACRT|HUMAN_QFIENGSEFAQK_2




sp|Q9GZZ8|LACRT|HUMAN_SILLTEQALAK_2




sp|Q9HC84|MUC5B|HUMAN_CADSSFTVLAELR_2




sp|Q9HC84|MUC5B|HUMAN_VCSTWGFDFHYK_3




sp|Q9NQ38-3|ISK5|HUMAN_ATAPTELCDDFK_2




sp|Q9NQ38-3|ISK5|HUMAN_AVFLTEALER_2




sp|Q9NZT1|CALL5|HUMAN_AFDQDGDGHITVDELR_2



sp|Q9NZT1|CALL5|HUMAN_AGLEDLQVAFR_2



sp|Q9UHA7|IL1F6|HUMAN_SFLFYHSQSQR_2



sp|Q9UHA7|IL1F6|HUMAN_VGDQPTLQLK_2

